Drug Interactions between Jevtana and Prezista
This report displays the potential drug interactions for the following 2 drugs:
- Jevtana (cabazitaxel)
- Prezista (darunavir)
Interactions between your drugs
darunavir cabazitaxel
Applies to: Prezista (darunavir) and Jevtana (cabazitaxel)
MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cabazitaxel, which is primarily metabolized by the isoenzyme. However, no formal drug interaction studies have been conducted.
MANAGEMENT: Caution is advised if cabazitaxel is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to cabazitaxel should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the cabazitaxel dosage adjusted as necessary. Regular monitoring of peripheral blood counts between treatment cycles is recommended, and patients should be advised to contact their physician if they experience potential signs and symptoms of cabazitaxel toxicity such as infection, fever, chills, diarrhea, unusual bruising or bleeding, and burning, tingling, or numbness in the hands and feet.
References
- "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
Drug and food interactions
darunavir food
Applies to: Prezista (darunavir)
ADJUST DOSING INTERVAL: Food enhances the absorption and oral bioavailability of darunavir administered in combination with low-dose ritonavir. The mechanism is unknown. When administered with food, the peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of darunavir were approximately 30% higher than when administered in the fasting state. Darunavir exposure was similar for the range of meals studied. The total caloric content of the various meals evaluated ranged from 240 Kcal (12 grams fat) to 928 Kcal (56 grams fat).
MANAGEMENT: To ensure maximal oral absorption, darunavir coadministered with ritonavir should be taken with food. The type of food is not important.
References
- "Product Information. Prezista (darunavir)." Ortho Biotech Inc (2006):
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.